it is a second generation retinoid it was subsequently removed from the canadian market in 1996 and the united states market in 1998 due to the high risk of birth defects it remains on the market in japan as tigason etretinate is a highly lipophilic aromatic retinoid it is stored and released from adipose tissue so its effects can continue long after dosage stops it is detectable in the plasma for up to three years following therapy etretinate has a low therapeutic index and a long elimination half life t of 120 days which make dosing difficult etretinate has been replaced by acitretin the free acid without the ethyl ester while acitretin is less lipophilic and has a half life of only 50 hours it is partly metabolized to etretinate in the body so that it is still a long acting teratogen and pregnancy is prohibited for two years after therapy side effects are those typical of hypervitaminosis a most commonly the drug was approved by the fda in 1986 to treat severe psoriasis it was subsequently removed from the canadian market in 1996 and the united states market in 1998 due to the high risk of birth defects in